Scholarlink

Objective <p>The aim of this study is to evaluate the effects of fisetin and atorvastatin administration on metabolic parameters and adipokine, hepatokine, and myokine profiles in rats fed a high-fat diet (HFD). Additionally, the effects of these agents on liver and skeletal muscle histology were investigated.</p> Methods <p>In the study, male Wistar albino rats were randomly divided into five groups: K(Control), Y(HFD), YF(HFD+Fisetin), YA(HFD+Atorvastatin) and YAF(HFD+Atorvastatin+Fisetin). The Y groups were fed a high-fat diet for 8 weeks. The intervention groups were administered fisetin (50&#xa0;mg/kg/day) and atorvastatin (10&#xa0;mg/kg/day) orally via gavage in addition to the high-fat diet for 8 weeks. At the end of the study, blood biochemistry, asprosin, fetuin-A, GDF-15, Metrnl, and histological changes in liver and gastrocnemius muscle tissue were examined.</p> Results <p>Histopathological examinations revealed significant structural damage in liver and muscle tissues in the Y (HFD) group compared to the control (C) group, while these damages were observed to be significantly reduced in the YAF group compared to the Y group. However, only limited effects were observed in biochemical data regarding LDL-C and TG levels; it was found that total cholesterol levels increased in the Y group compared to the K group, whereas decreases in glucose levels and improvements in creatinine and urea levels occurred in the treatment groups (YF, YA, and YAF) compared to the Y group. No significant differences were observed in adipokine, hepatokine, and myokine levels among the groups.</p> Conclusion <p>The combination of fisetin and atorvastatin significantly reduced HFD-induced liver and muscle tissue damage at the histological level. In terms of biochemical parameters, the combination therapy may be protective at the tissue level, but its effects on metabolic regulation may be limited depending on the dose and duration. Therefore, pharmacodynamic interactions and optimal dosage should be investigated in more detail.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of the Relationships of Fisetin and Atorvastatin with Adipokine, Hepatokine, Myokine Profiles and Metabolic Parameters in Rats Fed with High-Fat Diet

  • 期刊论文

  • 发表日期：

    2026年7月17日

查看全文
  • Seyit Muhammed Soycan,
  • Duygu İlke Yıldırım,
  • Fikret Akyürek,
  • Halil Güven,
  • Nejat Ünlükal,
  • Seda Atay,
  • Hakan Serin

摘要

Objective

The aim of this study is to evaluate the effects of fisetin and atorvastatin administration on metabolic parameters and adipokine, hepatokine, and myokine profiles in rats fed a high-fat diet (HFD). Additionally, the effects of these agents on liver and skeletal muscle histology were investigated.

Methods

In the study, male Wistar albino rats were randomly divided into five groups: K(Control), Y(HFD), YF(HFD+Fisetin), YA(HFD+Atorvastatin) and YAF(HFD+Atorvastatin+Fisetin). The Y groups were fed a high-fat diet for 8 weeks. The intervention groups were administered fisetin (50 mg/kg/day) and atorvastatin (10 mg/kg/day) orally via gavage in addition to the high-fat diet for 8 weeks. At the end of the study, blood biochemistry, asprosin, fetuin-A, GDF-15, Metrnl, and histological changes in liver and gastrocnemius muscle tissue were examined.

Results

Histopathological examinations revealed significant structural damage in liver and muscle tissues in the Y (HFD) group compared to the control (C) group, while these damages were observed to be significantly reduced in the YAF group compared to the Y group. However, only limited effects were observed in biochemical data regarding LDL-C and TG levels; it was found that total cholesterol levels increased in the Y group compared to the K group, whereas decreases in glucose levels and improvements in creatinine and urea levels occurred in the treatment groups (YF, YA, and YAF) compared to the Y group. No significant differences were observed in adipokine, hepatokine, and myokine levels among the groups.

Conclusion

The combination of fisetin and atorvastatin significantly reduced HFD-induced liver and muscle tissue damage at the histological level. In terms of biochemical parameters, the combination therapy may be protective at the tissue level, but its effects on metabolic regulation may be limited depending on the dose and duration. Therefore, pharmacodynamic interactions and optimal dosage should be investigated in more detail.